Browse peptides by goal and see what they may help with, what the risks are, and how strong the evidence is. Every review links to sources.
Showing 25 reviews
Dual GIP/GLP-1 agonist reviewed through SURMOUNT-5, SURPASS data, MASH findings, compounding rules, access, side effects, and comparison with semaglutide and Retatrutide.
FDA-approved GLP-1 receptor agonist sold as Ozempic, Wegovy, and Rybelsus, with STEP weight-loss data, SELECT cardiovascular outcomes data, rebound after stopping, GI tolerability issues, and active compounding controversy.
Eli Lilly investigational triple GLP-1/GIP/glucagon agonist. Phase 2 obesity data reached up to about 24% mean weight loss over 48 weeks; Phase 3 TRIUMPH-4 topline reported up to about 28.7% at 68 weeks on the highest dose. Still not FDA or EMA approved.
Approved in 35+ countries as Zadaxin, with hepatitis trial data, cancer adjuvant use, mixed COVID-19 evidence, and a clean safety profile across large clinical exposure.
FDA-approved GHRH analog reviewed for HIV-associated lipodystrophy, visceral-fat selectivity, cognitive RCT data, IGF-1 and glucose monitoring, and off-label use.
Brand-name cosmetic peptide family reviewed across four formulations, matrikine signaling, concentration problems, retinol comparison, GHK-Cu comparison, and topical safety.
Naturally occurring copper tripeptide with real topical skin and wound-healing evidence, a more cautious injectable evidence base, and copper-load safety considerations.
Russian-approved anxiolytic peptide derived from tuftsin, studied for anxiety relief without the sedation, dependency, or withdrawal profile associated with benzodiazepines. Human evidence is promising but still concentrated in Russian research.
Porcine brain-derived peptide mixture reviewed for stroke, TBI, dementia, approval controversy, Cochrane debate, MAOI contraindication, and grey-market sourcing risks.
Analyzing the neuroprotective and cognitive-enhancing effects of the ACTH analog. Comparison of limited clinical data vs. widespread research use.
NAD+ is a coenzyme central to aging, cellular energy, and DNA repair. Human trials show oral precursors can raise NAD+ levels, but the delivery debate, cancer context, and anti-aging claims still need careful interpretation.
Selective GHRP reviewed for GH release without significant cortisol, prolactin, or ACTH elevation, plus timing, CJC-1295 stack logic, WADA status, and limited human outcome data.
Synthetic GHRH analog with DAC and no-DAC versions, human GH and IGF-1 elevation data, insulin-resistance concerns, WADA prohibition, and no current drug approval.
Synthetic pineal tetrapeptide studied for telomerase activation, melatonin regulation, and anti-aging. The mechanism story is interesting and the animal data is real, but human proof remains thin and heavily concentrated in one Russian research ecosystem.
Synthetic Thymosin Beta-4 fragment discussed for systemic recovery, wound healing, and musculoskeletal repair. Most evidence comes from the parent compound TB4 rather than TB-500 itself, and it remains unapproved for human use.
Synthetic gastric-peptide fragment widely discussed for gut healing and tissue repair. Animal data is strong, but human evidence remains thin, long-term safety is unresolved, and it is not approved by major regulators.
Human antimicrobial peptide reviewed for membrane disruption, immune signaling, vitamin D induction, wound healing, cancer bidirectionality, psoriasis, and systemic-use uncertainty.
High-potency GHRP reviewed for GH pulse strength, rapid desensitization, cortisol and prolactin elevation, CD36 cardiac data, side effects, and WADA status.
Delta Sleep-Inducing Peptide has a misleading name, mixed sleep evidence, older human withdrawal data, and a short half-life that makes dosing and interpretation complicated.
Zinc-dependent thymic hormone reviewed for T cell education, zinc cofactor biology, biphasic zinc response, pain modulation research, and aging-related thymic decline.
Synthetic hGH 176-191 fragment developed for obesity, with a clean safety profile but failed late-stage fat-loss trials. The more interesting research path now is cartilage and joint repair, not standalone weight loss.
Mitochondrially encoded peptide reviewed for discovery history, HNG potency, centenarian correlation, cell-protection data, and the missing human interventional evidence.
Angiotensin-IV derivative reviewed for synaptogenesis, HGF/c-Met signaling, oral bioavailability, no published human trials, unknown dosing, and theoretical cancer concerns.
Khavinson tripeptide bioregulator reviewed for Pinealon vs Epitalon, Cortexin translation gap, gene-expression claims, neuroprotection data, and Russian-literature concentration.
Unapproved non-selective melanocortin agonist reviewed for tanning mechanism, mole darkening, ocular risk, severe nausea, illegal-market use, and long-term safety concerns.